Skip to content
Biodatica
Start free

Novo Nordisk A/S

Birmingham, Alabama

OncologyPhase IIIListed · NVO

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Study registered, no phase assigned: Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

5w agoTrial registeredJun 11, 2026Source filing (opens the source filing in a new tab)

Momentum

82no change

Momentum 82 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Apr 30, 2024

    Diabetes Mellitus, Type 2 · COMPLETED · sponsor: Novo Nordisk A/S · Remote Study Collecting Blood Glucose Values and Activity Data in Patients With Type 2 Diabetes on Different Treatments

    ClinicalTrials.gov · NCT04809311 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Jan 26, 2021

    Diabetes Mellitus, Type 2 · COMPLETED · sponsor: Novo Nordisk A/S · Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data

    ClinicalTrials.gov · NCT04572165 (opens the source filing in a new tab)

  3. Trial

    PHASE3 registered

    Oct 1, 2020

    Diabetes Mellitus, Type 2, Peripheral Arterial Disease · COMPLETED · sponsor: Novo Nordisk A/S · A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes

    ClinicalTrials.gov · NCT04560998 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources